Skip to content
Search

Latest Stories

After Robbie Turner, Gail Fleming leaves RPS

Gail Fleming, the director of Education and Professional Development at the Royal Pharmaceutical Society, has decided to resign. Thursday, April 7 will be her last day at the RPS.

In a statement, chief executive Paul Bennett said: “On the 4th March we announced that we were proposing some changes to our executive structure.


“Further to my update on the 24th of March I can announce that Gail Fleming has decided to leave her role as Director of Education and Professional Development and her last day with us will be 07 April 2022."

Bennett wished Fleming luck and thanked "her for her excellent work since joining the organisation in 2018".

He added: “I will be updating everyone on how any changes to our structure enable us to deliver our Royal Charter obligations and our five-year strategy.”

Robbie Turner Robbie Turner

Last week, RPS also announced that "Robbie Turner has decided to leave his role as director of Pharmacy and Membership Experience and his last day with us will be 31 March 2022."

Earlier, on a proposed change to the executive structure, RPS president Claire Anderson commented: “I deeply regret seeing so much speculation in the public domain about a proposed change to the Executive Team when no decision has yet been made, and feel for those involved.

“This is an organisational decision, as it is about operational matters. RPS finances are on a secure footing and this proposal is not about cost savings. We intend to continue our investment in education and professional leadership for the future of the pharmacy profession.

“Our excellent and dedicated teams will continue to advocate on behalf of the profession across all sectors and areas of practice, including education, workforce issues, independent prescribing and inclusion and diversity.

"In particular, our work on education, including post-registration curricula, assessment and credentialing, workforce planning, leadership development and mentoring are strategically important to our profession, right from undergraduate level through foundation to advanced and consultant practice.

"We are completely committed to maintaining this work and should the proposal go ahead, there would still be a leader on the Executive with responsibility for delivering on our education strategy."

In March, RPS said that it had identified two roles at potential risk of redundancy, but did not specify which two roles were going to be axed.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less